Vita Dolžan - Concepedia

Author

Vita Dolžan

Also Known As

Dolzan Vita, Dolžan Vita, Dolžan, Vita, Katja Goričar, Prainsack, Barbara, Reinhard Würzner, V Dolzan, V Dolz̆an, V Dolž;an, V Dolžan

290

Publications

7.7K

Citations

H-Index

129

Concepts

All Affiliations

University of Ljubljana Ljubljana University Medical Centre Institute of Oncology Ljubljana University Psychiatric Hospital University of Bologna

About

Vita Dolžan is an author at University of Ljubljana specializing in medicine, pharmacology, and genetic epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	42	3.2K
2	Public Health	9	9	1.6K
3	Health Sciences	4	4	124
4	Social Sciences	3	3	92
5	Engineering	2	2	50

Vita Dolžan

130

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Metabolic gene polymorphism frequencies in control populations. Seymour Garte, Laura Gaspari, Anna-Karin Alexandrie, PubMed GeneticsGenetic EpidemiologyHuman PolymorphismGenotype-phenotype AssociationMolecular Ecology	2001	847
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson, The Lancet Drug SafetyAdverse Drug ReactionsPharmacoepidemiologyPharmacologyPharmacogenomics	2023	462
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium Cathelijne H. van der Wouden, Anne Cambon‐Thomsen, Erika Cecchin, Clinical Pharmacology & Therapeutics Relevant Pgx-markersGenetic EpidemiologyUbiquitous PharmacogenomicsGenetic MedicineTranslational Medicine	2016	288
Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk Simone Benhamou, Won Jin Lee, Anna-Karin Alexandrie, Carcinogenesis	2002	255
A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics Clint Mizzi, Eleni Dalabira, Judit Kumuthini, PLoS ONE Genetic EpidemiologyGenome-wide Association StudyBiomarker (Medicine)Pharmacogenomics BiomarkersBiostatistics	2016	153
Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism Petra Bohanec Grabar, D Logar, B Lestan, European Journal of Clinical Pharmacology Rheumatoid DisorderRheumatologyAutoimmune DiseaseAllergyMedicine	2008	124
CYP1A1 T<sup>3801</sup> C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls Paolo Vineis, Fabrizio Veglia, Simone Benhamou, International Journal of Cancer	2003	123
The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement Darja Herman, Polona Peternel, Mojca Stegnar, Thrombosis and Haemostasis GeneticsGenetic EpidemiologyFactor ViiHuman PolymorphismPharmacotherapy	2006	121
Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose Darja Herman, Igor Locatelli, Iztok Grabnar, The Pharmacogenomics Journal ThrombosisCardiovascular DiseaseGenetic EpidemiologyPharmacologyHuman Polymorphism	2005	121
Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years Emanuela Taioli, Laura Gaspari, Simone Benhamou, International Journal of Epidemiology	2003	111

Page 1